Preliminary evaluation of miR-1307-3p in human serum for detection of 13 types of solid cancer using microRNA chip.

Early detection and treatment are crucial for increasing the five-year survival rates of various cancers. Low-cost and convenient cancer screening tests are also critically important. Circulating microRNAs are reported as potential biomarkers for various cancers. Recently, miR-1307-3p was found to be a cancer-related microRNA. We evaluated the expression levels of miR-1307-3p in sera obtained from 254 patients with thirteen types of cancer (colon cancer, lung cancer, gastric cancer, liver cancer, bladder cancer esophageal cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, biliary tract cancer, brain cancer, sarcoma) and 27 non-cancer samples using isothermal amplification and microRNA chip. The expression levels of miR-1307-3p in sera obtained from cancer patients were clearly different from those obtained from non-cancer samples and differentiated the validation cohort into cancer patients and non-cancer control with high accuracy (AUC: 0.98; sensitivity: 0.98; specificity: 0.85). These results showed the potential relevance of miR-1307-3p in serum for the development of new diagnostic examination tools for cancer patients.